Roche ditch­es fi­nal PhI­II for can­cer hope­ful, re­ports set­back for key drug in $1.4B buy­out

Over the past few years, Roche has re­leased news about its AKT in­hibitor ipatasert­ib in drips — most of them neg­a­tive. The drug yield­ed mixed da­ta in a key prostate can­cer tri­al, Phase III flops in triple-neg­a­tive breast can­cer forced the phar­ma gi­ant to pull the plug there, and in mid-2022 Roche trimmed two more ear­ly-stage in­di­ca­tions in prostate can­cer af­ter com­plet­ing the tri­als.

Now, the last piece of the pro­gram is gone.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER